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Spinal cord stimulation (SCS) is a form of therapy 
with a supportive evidence base, and has been used 
for the treatment of pain since 1967. It is strategically 
aimed at reducing the unpleasant sensory experience 
of pain and the consequent functional and 
behavioural effects that pain may have. When SCS is used to treat 
patients with chronic pain, it is important that the treatment is 
delivered within the context of a full understanding of the impact 
that pain has upon the patient, including its effect on quality of life. 
Pain can and does affect patients’ psychological well-being and social 
functions. These recommendations give guidance to practitioners 
delivering this treatment, to those who may wish to refer patients 
for SCS, and to those who care for patients with stimulators in situ. 
The recommendations also provide a resource for organisations that 
fund SCS.
1. Executive summary
1.1.  Persistent pain is common. Whereas acute pain may only impact 
by interrupting current activity, episodic and persistent pain is 
likely to interfere with one or more aspects of a person’s life and 
to affect his or her sense of identity.
1.2.  There is clinical evidence from randomised controlled trials 
(RCTs) to support the use of SCS for pain from failed back surgical 
syndrome (FBSS), complex regional pain syndrome (CRPS), 
neuropathic pain, and ischaemic pain. The National Institute for 
Clinical Excellence (NICE) published guidance on SCS for chronic 
pain of neuropathic or ischaemic origin in 2008 (ref – TA 159). 
It recommended SCS for severe, prolonged pain responsive to a 
trial of stimulation in FBSS, CRPS, and neuropathic pain. NICE 
concluded that there was insufficient evidence of cost-effectiveness 
to recommend the use of SCS outside of controlled trials in 
ischaemic pain. We concur that further high-quality research on 
the use of SCS for chronic pain of ischaemic origin is required.
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1.3. Not all patients are suitable for SCS.
1.4.  A multidisciplinary pain-management team is the most 
appropriate context in which to provide SCS.
1.5.  Not all patients will have the resources to receive SCS therapy, 
but this does not detract from the evidence supporting its use. It 
remains an appropriate form of therapy.
1.6.  Members of the team must include clinicians competent to deal 
with the complications of SCS.
1.7.  SCS may be delivered in parallel with other therapies and should 
be used as part of an overall rehabilitation strategy.
1.8.  Techniques of SCS vary. Clinical teams must have and maintain 
the competencies needed to offer the most appropriate technique 
according to an individual patient’s needs.
1.9.  Clinicians performing this intervention should insert a sufficient 
number of SCS systems to maintain competence (see 5.8).
1.10.  SCS must be performed in an operating theatre environment 
suitable for implant work, with appropriate anaesthesia and post-
anaesthesia care facilities. Patients must have comprehensive 
access to advice if they experience problems with the stimulating 
system.
1.11.  The most common organism to infect SCS systems is 
Staphylococcus aureus. 
1.12.  SCS is a long-term treatment for a chronic condition, and 
appropriate infrastructure for ongoing surveillance and support 
must be in place.
1.13.  The compatibility of SCS with magnetic resonance imaging (MRI) 
is problematic. While there have now been small series of cases 
reported without problems, concerns remain and other imaging 
modalities should be used if at all possible. If MRI is required, 
the advice of a radiologist should be sought and, depending on 
imaging site and sequencing, imaging may be possible. However, 
at present, the majority of radiologists would not advise using MRI 
with an SCS in situ. 
2. Need for recommendations
2.1.  Persisting pain occurs in up to one-half of the adult population 
at some time in their lives. One in 10 adults with persisting pain 
would describe themselves as being severely disabled by it. Most 
patients with chronic pain can be managed in primary care, 
but some need specialised, multidisciplinary assessment and 
management.
2.2.  Patients who are referred to a pain service have frequently seen a 
number of other secondary-care specialists and have usually been 
extensively investigated.
2.3.  Multidisciplinary pain services should offer patients a range of 
evidence-based interventions. It is rarely possible to provide 
complete pain relief. Patients should also be offered advice on 
self-management and coping strategies, in tandem with any 
interventions.
2.4.  Persisting pain is difficult to treat, and some patients will 
continue to experience intrusive and distressing symptoms 
despite a variety of surgical and electro-thermal interventions.
2.5.  SCS may be helpful in carefully selected patients. However, many 
patients will not be helped by SCS.
2.6.  Some indications for SCS are well-established (e.g. FBSS, CRPS, 
neuropathic pain, refractory angina pectoris (RAP), peripheral 
vascular disease), and others are emerging (e.g. visceral pain, 
interstitial cystitis). As knowledge and expertise develop, the 
techniques change and may be refined. 
2.7.  At the time of writing, many patients in SA are refused therapy 
with SCS due to lack of funds, or to medical assessors’ lack of 
knowledge on the subject. This does not imply that this form 
of therapy is not well-established or not supported by good 
scientific studies.
2.8.  The recommendations will:
a) Guide healthcare professionals regarding:
• Whom to refer
• Whom not to refer
• What to tell patients
• How to look after patients who have had SCS implanted
• How to deal with complications after SCS implantation. 
b)  Promote best clinical practice for clinical teams involved in 
providing SCS, to enable them to:
• Select patients appropriately
• Prepare patients for the therapy
• Deliver SCS safely with minimal morbidity
• Optimise outcomes
• Provide appropriate continuing care.
c) Allow patients to make an informed decision.
d)  Inform commissioners of healthcare services and medical 
funders.
3. Scientific rationale
3.1.  The use of stimulation techniques in modern pain medicine 
dates from the publication of the gate theory of Melzack and 
Wall in 1965, which described how stimulating neural pathways 
carrying innocuous (non-painful) information could influence 
the onward transmission of noxious information in the nervous 
system.
3.2.  Although the introduction of SCS was inspired by the gate theory, 
its mechanism of action involves more than a direct inhibition of 
pain transmission in the dorsal horn of the spinal cord. If this were 
the principal mode of action, then SCS would control nociceptive 
pain, and this is not generally the case. Pain modulation by SCS 
also involves supra-spinal activity via the posterior columns 
of the spinal cord, probably recruiting endogenous inhibitory 
pathways. There is also a pronounced autonomic effect, though the 
mechanisms of this are not fully understood.
3.3.  The preservation of topographically appropriate posterior column 
function seems to be necessary for SCS to be effective, but there is 
debate regarding which elements are necessary and to what degree.
4. Evidence
4.1.  RCTs of SCS have been undertaken for FBSS, complex CRPS type 
1, RAP, and chronic critical limb ischaemia (CLI). A summary of 
these RCTs and their findings is listed in Appendix 2. In addition 
to RCT evidence, systematic reviews of SCS have included case 
series and observational comparisons, particularly for FBSS and 
CRPS (see Appendix 2). It should be noted that present funding 
models in SA include only FBSS, CRPS, and some peripheral 
neuropathies including post-herpetic neuralgia (PHN) and 
diabetic peripheral neuropathy (DPN). These guidelines do 
include some data on the other described pathologies but shall 
be more focused on the former conditions.
• RCTs demonstrate that SCS is more effective for radicular 
(limb) pain following spinal surgery than either reoperation or 
management by nonsurgical therapy.
4.2.  NICE published guidance on SCS for chronic pain of neuropathic 
or ischaemic origin in 2008 (ref – TA 159). With provisos regarding 
the severity and duration of pain and a trial of stimulation 
after multidisciplinary assessment, SCS is recommended as a 
treatment option for adults with chronic pain of neuropathic 
origin. This recommendation was based on RCT data and robust 
cost-effectiveness analyses for trials in FBSS and CRPS. The 
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recommendation was extended to include all causes of chronic 
pain of neuropathic origin on the advice of nominated specialists. 
SCS is not, however, recommended for chronic pain of ischaemic 
origin, except in the context of research as part of a clinical trial.
4.3.  NICE felt unable to recommend SCS for chronic pain of 
ischaemic origin for two reasons: lack of high-quality RCT data, 
and insufficient data to support robust economic modelling. 
Functional outcomes were considered in addition to improvements 
in pain levels.
4.4.  In the case of CLI, NICE acknowledged that non-randomised 
evidence suggests there may be functional benefit for certain 
sub-groups of people. The evidence for improvement in health-
related quality of life was not robust, and it was not possible to 
perform a cost-effectiveness analysis.
4.5.  With regard to RAP, NICE assessed that the available data did not 
allow accurate identification of the population to be treated, or the 
available comparator treatments. The committee accepted that SCS 
was as effective as comparator treatments in the included studies. 
Again, no cost-effectiveness analysis was possible.
4.6.  We concur with NICE that further high-quality research on the 
use of SCS in chronic pain of ischaemic origin is required.
5.  SCS: Appropriate context for delivery
5.1.  Pain interferes with physical function and is often associated 
with psychological problems. All patients being considered for 
SCS must be assessed with regard to physical, psychological, and 
social functioning.
5.2.  An important approach to the treatment of pain is to attempt 
to modulate the unpleasant sensory experience by reducing 
the intensity, duration and frequency with which pain is felt. 
Medication, nerve blocks, physical therapies and SCS are all 
strategies used to achieve this outcome. SCS should not be 
considered as a first line of therapy, and other non-invasive 
options for treating the pain should be considered first.
5.3.  Psychological interventions – mainly cognitive-behavioural 
therapy (CBT) – are largely focused on mitigating the interference 
in function that persistent pain induces. Such treatments may be 
offered in conjunction with SCS.
5.4.  Qualitative psychological testing does not predict outcome, but 
assessment by a psychologist is desirable to assess the patient’s 
beliefs, expectations, and understanding of the treatment in 
relation to the condition. 
5.5.  A multidisciplinary pain-management team is the most 
appropriate context in which to provide SCS. Such a team should 
be able to deliver a range of therapies for pain.
5.6.  The team will usually comprise several professionals. Members 
may include a consultant in pain medicine and one or more 
consultants from other relevant specialties, e.g. neurosurgery, 
spinal surgery, cardiology, or vascular surgery. Other members 
of the team might include psychologists, physiotherapists, and 
nurse specialists in pain management. The team must have access 
to a spinal surgeon or neurosurgeon competent to deal with the 
complications of SCS.
5.7.  Clinicians performing the SCS interventions must understand 
the multidisciplinary management of pain. They must have and 
maintain relevant surgical competence in insertion of the SCS 
system and management of complications such as infection. 
This will usually be in the form of a consultant in pain medicine, 
neurosurgeon, or spinal surgeon.
5.8.  The competence of the implanter and the activity and competence 
of the team must be maintained. Where a new service is being 
established, there should be evidence of progression toward an 
annual caseload that will maintain competence, or the opportunity 
to regularly work within other units that have a high level of 
activity. 
5.9.  SCS is a long-term therapy. Teams must have appropriate 
arrangements for ongoing patient care, including availability 
to investigate and manage potentially serious problems such as 
neurological deficit, bleeding or infection. SCS is a significant 
commitment for patients and their healthcare team, and it is not 
usually appropriate for a single consultant to manage this therapy 
without the support of colleagues.
6. Patient selection
6.1.  Patients must have an up-to-date assessment in relation to the 
indication for SCS.
6.2.  History and physical examination should be detailed.
6.3. The indications for SCS are summarised in Table 1.
6.4.  The use of SCS for other conditions such as pelvic and visceral 
pain has been described. Its use in these and other emerging 
indications should carefully be audited.
6.5.  Contraindications to the use of SCS are summarised in Table 2.
6.6.  Considerations regarding surgical insertion of plate electrodes 
are summarised in Table 3.
6.7.  Many patients, such as those with pain following spinal surgery, 
will present a mixed neuropathic/nociceptive picture. Patients 
should be told that SCS will probably only help part of their pain. 
Teams offering SCS must be able to deliver appropriate additional 
therapies, including pain management programmes.
6.8.  Physical and psychological co-morbidity does not preclude 
treatment with SCS. Patients with concurrent physical or mental 
illness should be assessed in close conjunction with relevant 
clinical teams. Cognitive impairment, communication problems, 
or learning difficulty resulting in failure to understand the therapy 
are not reasons to exclude patients from SCS, but these patients 
must have a cognizant caregiver and adequate social support.
6.9.  The management of children being considered for SCS should 
be in conjunction with a specialised multidisciplinary children’s 
pain management team.
7. Timing
7.1.  SCS may be delivered in conjunction with other therapies such 
as medication and psychologically based therapies. If there is 
significant psychological distress identified at assessment, such 
patients may benefit from individual psychological therapy (e.g. 
CBT) before proceeding to SCS. For those patients who may also 
benefit from a pain management programme, it is preferable to 
provide that treatment before SCS.
7.2.  SCS should be considered early in the patient’s management 
when simple first-line therapies have failed. SCS should not 
necessarily be considered a treatment of last resort.
7.3.  Cognitive impairment resulting in failure to understand the 
therapy is not a reason to exclude patients from SCS, but these 
patients must have a cognisant carer and adequate social support.
8. Techniques of stimulation
8.1.  Stimulation of the spinal cord is by an implanted electrode 
powered by an implanted pulse generator (IPG). Electrodes 
may be inserted percutaneously via an epidural needle or 
surgically implanted via laminotomy. Electrodes may be bipolar 
or multipolar, and multiple electrodes may be used. Pulses 
are generated by a fully implantable battery-powered device. 
Rechargeable battery systems are now available and may be 
preferred for some patients such as those who require high 
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current use (including systems with multiple electrodes), as these 
batteries have been proven to be cost-effective.
8.2.  Electrodes must be placed to elicit paraesthesia that covers the 
region of reported pain.
8.3.  It is recommended that percutaneous electrodes be placed under a 
local anaesthetic with minimal sedation. This optimises electrode 
placement and reduces the risk of inadvertent neural trauma.
8.4.  Surgical electrodes require open surgery (laminotomy or partial 
laminectomy) for placement. This is usually carried out under a 
general anaesthetic. Such electrodes are less likely to be dislodged.
8.5.  The electrode/s should be connected temporarily to an external 
stimulating device before proceeding to insertion of an IPG. This 
allows the patient to undergo a period of trial stimulation during 
which time pain relief, improvement in function, and reduction 
in medication may be assessed. If the outcome of the trial is 
favourable, then the patient may wish to proceed to IPG insertion.
8.6.  The same team should carry out trial stimulation and definitive 
implantation.
8.7.  Following IPG insertion, the patient may switch the device on 
and off with a hand-held programmer and may vary voltage and 
frequency within physician-determined limits.
8.8.  IPG battery life is variable, but is usually between 2 and 8 
years depending on the pattern of use and the output required. 
Rechargeable batteries with increased longevity are now available.
8.9.  Centres offering SCS to patients should ensure that the service 
is appropriately funded to support ongoing system maintenance, 
including the need for IPG replacement in those patients who 
do not have a rechargeable system in situ, and the possible need 
for lead or system revision. Patients must be made aware of all 
matters relating to funding prior to any SCS procedure.
9. The procedure
9.1 Preoperative assessment and preparation
9.1.1.  Patients must be investigated appropriately to determine their 
fitness to undergo surgery and anaesthesia or sedation.
9.1.2.  The most common organism to infect SCS systems is S. aureus. 
9.1.3.  The patient and operator should agree preoperatively on the 
proposed position of the IPG.
9.1.4.  There is little published evidence regarding the use of antibiotic 
prophylaxis for SCS. Infection of an SCS system can be a 
significant problem and therefore its consequences justify the use 
of antibiotic prophylaxis. Antibiotics should be given as a single 
intravenous dose prior to starting the procedure. Appropriate 
cover for S. aureus should be ensured.
9.2 The theatre environment
9.2.1.  Standard operating and post-anaesthesia care facilities must 
be available.
9.2.2.  The operating theatre must be suitable for implant work. A 
laminar flow environment is suggested.
9.2.3.  X-ray screening is mandatory for percutaneous lead placement.
9.2.4.  A practitioner skilled in programming and trialing SCS must be 
present for the percutaneous procedures. 
Table 2. Medical contraindications to the use of SCS 
•   Uncontrolled bleeding disorder; ongoing anticoagulant therapy 
is a relative contraindication
•  Systemic or local sepsis
•   Presence of a demand pacemaker or implanted defibrillator 
(relative contraindication)
•  Immune suppression (relative contraindication)
Table 3. Surgical insertion of electrodes: Special considerations
•   General contraindications to surgery should apply, such as 
coagulopathy or sepsis
•   Surgical electrode systems are larger than percutaneous systems; 
to avoid the risk of cord compression, special note must be taken 
of the possibility of spinal canal stenosis if the electrodes are to be 
inserted beneath intact/residual laminae. Pre-operative MRI of 
the target area of the spine should be considered (if not already 
performed)
•   Extensive laminectomy (particularly in the cervical spine) 
has potential morbidity. The appropriateness of further 
laminectomy to insert electrodes must be considered 
carefully when patients have previously undergone extensive 
laminectomy in or adjacent to the target area
•   Open insertion of an electrode permits fixation of the electrode 
to the dura. If this option is taken, then sutures should 
pass through only the outer layer of the dura to avoid the 
development of a cerebrospinal fluid (CSF) hygroma
•   Approximately 5% of people undergoing thoracic laminectomy 
may experience postoperative thoracic backache persisting for 
weeks or months. Patients should be warned of this possibility
MRI = magnetic resonance imaging; CSF = cerebrospinal fluid.
Table 1. Types of pain and level of indication for SCS
Level of indication Type of pain
Good indications 
(likely to respond)
• Neuropathic pain in leg or arm 
following lumbar or cervical spine 
surgery (FBSS/FNSS)
• CRPS
• Neuropathic pain secondary to 
peripheral nerve damage
• Brachial plexopathy: traumatic (partial, 




• Amputation pain (stump pain responds 
better than phantom pain)
• Axial pain following spinal surgery 
(if there is a neuropathic component 
accompanying the axial pain)
• Intercostal neuralgia, such as post-
thoracotomy or post-herpetic neuralgia
• Pain associated with spinal cord 
damage but maintaining posterior 
column functioning (other peripheral 
neuropathic pain syndromes, such as 
those following trauma may respond)
Poor indications 
(rarely respond)
• Central pain of non-spinal cord origin
• Spinal cord injury with clinically 
complete loss of posterior column 
function
• Perineal or anorectal pain
Unresponsive • Complete spinal cord transection
• Non-ischaemic nociceptive pain
• Nerve root avulsion
FBSS = failed back surgical syndrome; FNSS = failed neck surgical syndrome; 
CRPS = complex regional pain syndrome.
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9.3 Post-anaesthesia care and ward management
9.3.1.  Programming the SCS should not begin until the patient is 
fully conscious.
9.3.2.  Ward staff should be familiar with the aims and procedure of 
SCS, the condition that it is being used to manage, and the 
potential complications that may arise.
9.3.3.  The post-operative observation regimen should consider 
potential complications such as spinal cord compression, 
neurological injury, bleeding, and infection.
9.3.4.  Ward staff should be able to seek advice from a member of the 
implant team at any time.
9.4 Discharge and ongoing care
9.4.1.  Adequate arrangements must be made for the implant team to 
conduct surveillance and follow-up; the patient should be able to 
contact an appropriate and experienced professional at any time.
9.4.2.  Referring physicians must be given advice about all patients 
who are sent home after SCS implant.
9.4.3.  In the event of complications related to the SCS or other 
pathology, there should be established relationships with other 
relevant disciplines such as spinal surgery and neurosurgery, 
microbiology and neuroradiology.
9.4.4.  SCS is a long-term treatment for a chronic condition. Patients 
with non-rechargeable systems will need IPG replacement at 
some stage. Mechanisms should be in place to predict when this 
is likely to occur, so that, with planning, SCS function can be 
restored promptly.
9.4.5.  If patients move beyond a reasonable travelling distance from 
the implanting centre, systems must be in place to transfer their 
care appropriately to other physicians.
10. Special precautions
10.1.  Unipolar diathermy should be avoided in patients with SCS 
in situ. If its use is unavoidable, the reference plate should be 
positioned so that the SCS components are outside the electrical 
field of the diathermy.
10.2.  The interaction of MRI and SCS is complex. The magnetic 
field may cause leads to move, resulting in loss of effect or 
neural damage, or heat the implant components, resulting in 
discomfort, tissue damage, or software malfunction. In addition, 
the location of the leads in relation to the site of imaging interest 
may corrupt the image. Patients with SCS in situ who need 
investigation with MRI may pose specific problems that should 
be discussed with an experienced neuro-radiologist. If there 
is any doubt about the compatibility, then alternative imaging 
(such as computed tomography (CT) scan or myelography) 
should be performed. It has been established that if MRI studies 
are unavoidable, then the IPG should be switched off during the 
scans and thereafter checked for programming errors.
10.3.  The presence of a cardiac pacemaker is a relative contraindication 
to SCS. Most contemporary pacemakers are operated in the 
demand mode – they monitor intrinsic cardiac activity, and 
may be inhibited by spontaneous extra-cardiac electrical 
activity. They may sense extraneous electrical activity from SCS 
devices and misinterpret it as appropriate cardiac activity. The 
pacemaker may then either respond by inhibiting pacing or by 
reverting to an asynchronous pacing mode. Inhibition of pacing 
can be potentially dangerous for the patient; asynchronous 
pacing is less serious, but still compromises pacemaker function. 
In such circumstances, it has been suggested that bipolar 
pacemaker sensing should be employed, as it is inherently less 
sensitive to extraneous signals than the unipolar pacing mode.
10.4.  Patients should be advised that airport (and other) security 
systems may be activated by a stimulator. Patients should carry 
information relating to their SCS in situations where this may 
be relevant.
10.5.  Patients must inform their medical caregivers that they have 
SCS in place.
10.6.  Short-wave diathermy, microwave diathermy, and therapeutic 
ultrasound diathermy are hazardous in patients with SCS.
10.7.  Antibiotic prophylaxis is not recommended for patients with 
SCS systems in situ who are undergoing incidental procedures 
that may generate bacteraemia.
11. Complications of SCS
11.1.  SCS has been used in many thousands of patients worldwide; 
some clinical centres have reported follow-up of >10 years. 
Major complications of SCS are rare, but minor ones are 
common. Most problems are technical, with the most common 
complication being lead migration. These complications should 
be discussed during the consent process. 
11.2.  Neurological damage relating to epidural electrode placement is 
a rare complication and may occur with both percutaneous and 
surgical electrodes. Damage may occur directly or from epidural 
haematoma or infection. These latter complications are reversible 
if diagnosed and treated promptly, emphasising the importance 
of postoperative neurological observations by experienced staff. 
Vigilance and access to early imaging are essential (see 10.2).
11.3.  Dural puncture may occur during percutaneous insertion 
of electrodes. This happens most frequently with the Tuohy 
needle, but may occur with the guide wire or the stimulating 
electrode. 
11.4.  Infection of implanted neurostimulators is a serious problem 
and must never be ignored. Usually, the infection will not 
resolve unless the whole SCS system is explanted. Infection of 
the entire system is rare but can result in epidural abscess with 
potentially disastrous neurological consequences. In such cases 
explantation is required.
11.5.  Patients should be aware that not only will surgery be necessary 
to replace a depleted IPG but that it may also be necessary to 
revise the electrodes or connections.
11.6.  Electrode migration (see 11.1) may occur immediately 
following the procedure, at any time during the trial period 
or following IPG insertion. Cervical electrodes are more likely 
to be dislodged than those in the thoracic region. Migration 
is less likely with surgical electrodes. Recent improvements in 
anchor designs have been shown to reduce migration.
11.7.  Other potential problems include fluid entering the connectors 
or electrode, lead breakage, and disconnection.
12. Patient information
12.1.  The risks and limitations of SCS should be discussed with 
patients, who should be given written information in a form 
that they can understand.
12.2.  Patients must be aware of the evidence for the efficacy of SCS for 
the indication in their case.
12.3.  Patients should be given information relating to complications 
and outcomes.
12.4.  Detailed information regarding the procedure of SCS insertion, 
including the operating theatre environment, is necessary.
12.5.  Patients should understand that SCS provides benefit only as 
part of a multidimensional approach to symptom management.
12.6.  Patients should understand the need for ongoing care following 
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Appendix 1. SCS literature review 
This review is based on the recently published recommendations of the British Pain Society: The British Pain Society’s Spinal Cord 
Stimulation for the Management of Pain: Recommendations for Best Clinical Practice – a consensus document prepared on behalf of the 
British Pain Society in consultation with the Society of British Neurological Surgeons.
Search method
RCTs and systematic reviews were identified from searches of MEDLINE (PubMed) and the Cochrane Library based on a search conducted 
on 5 January 2004 and updated in September 2008.
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12.7.  Patients must be given adequate time to consider the benefits 
and burdens of the technique before consenting to treatment.
13. Audit
13.1.  There is currently no national database of SCS patients.
13.2. Local audit of implanted patients is recommended.
13.3.  Formal professional communication between implanting centres 
is strongly recommended.
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Appendix 2. Summary of SCS RCTs
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Appendix 2 (continued). Summary of SCS RCTs
First author   




United Kingdom 10 SCS v. no SCS 
(stimulator implanted 
but not activated)






















































Netherlands 37 SCS + best medical care 








Netherlands 120 SCS + conventional 
medical care v. 
conventional medical 
care alone


















112 SCS + best medical care 







SCS = spinal cord stimulation; RAP = refractory angina pectoris; ECG = electrocardiogram; FBSS = failed back surgical syndrome; CRPS = complex regional pain syndrome; CLI = critical limb ischaemia; 
PGE1 = prostaglandin E1; TcPO2 = transcutaneous oxygen pressure; ABPI = ankle brachial pressure index.
* Number of patients randomised.
† Latest follow up reported with groups randomisation maintained.
‡ Mean follow-up.
§ Results taken from Cochrane view.
¶ Results with p≤0.05 were considered statistically significant:
   + Improvements in outcome in SCS group v. comparator group at follow up (p≤0.05).
   – Decrement in outcome in SCS group v. comparator group at follow up (p≤0.05).
   = Difference in outcome between SCS group v. comparator group at follow up (p>0.05).
